Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2011 Dec 20;13(1):70; author reply 70.
doi: 10.1038/nrn3110-c1.

Corticotropin-releasing factor: innocent until proven guilty

William J Giardino, Andrey E Ryabinin
Comment

Corticotropin-releasing factor: innocent until proven guilty

William J Giardino et al. Nat Rev Neurosci. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

Competing interests statement

The authors declare no competing financial interests.

Figures

Figure 1
Figure 1. Relationships among corticotropin-releasing factor (CRF), urocortins and their targets
CRF has high affinity for CRF receptor 1 (CRF1) and CRF binding protein (CRFBP), urocortin 2 (UCN2) and UCN3 are selective for CRF receptor 2 (CRF2), and UCN1 has high affinity for both receptors and the CRFBP. Solid lines indicate high-affinity binding, dashed lines indicate species-dependent affinity.
See this image and copyright information in PMC

Comment on

References

    1. Heilig M, Goldman D, Berrettini W, O’Brien CP. Pharmacogenetic approaches to the treatment of alcohol addiction. Nature Rev Neurosci. 2011;12:670–684. - PMC - PubMed
    1. Reul JM, Holsboer F. Corticotropin-releasing factor receptors 1 and 2 in anxiety and depression. Curr Opin Pharmacol. 2002;2:23–33. - PubMed
    1. Le AD, Harding S, Juzytsch W, Fletcher PJ, Shaham Y. The role of corticotropin-releasing factor in the median raphe nucleus in relapse to alcohol. J Neurosci. 2002;22:7844–7849. - PMC - PubMed
    1. Perrin MH, Sutton SW, Cervini LA, Rivier JE, Vale WW. Comparison of an agonist, urocortin, and an antagonist, astressin, as radioligands for characterization of corticotropin-releasing factor receptors. J Pharmacol Exp Ther. 1999;288:729–734. - PubMed
    1. Bittencourt JC, et al. Urocortin expression in rat brain: evidence against a pervasive relationship of urocortin-containing projections with targets bearing type 2CRF receptors. J Comp Neurol. 1999;415:285–312. - PubMed

Substances